Regulatory Clearance Is Not Commercial Readiness

TL;DR

Regulatory clearance confirms the device meets the applicable requirements for market entry. It doesn’t tell you whether you can build it repeatably, at the volume and cost your business model needs. Those are two different questions, and plenty of teams find out they’ve only answered the first one after the commercial clock has already started.

The finish line everyone aims at is the wrong one

Clearance gets treated as the finish line because it’s the milestone everyone outside engineering can see. Investors ask about it, boards track it, and press releases announce it. Meanwhile the supply chain, the process documentation, and the cost structure sit untested at anything past clinical build volumes.

That gap is where cleared devices stall. The design is largely locked, the clock is running on cash and competitors, and going from twenty units to two thousand turns out to be a different problem rather than more of the same.

Boston Scientific’s Lotus Edge valve is one public example. It won FDA approval in 2019 and was discontinued in 2020, with the company citing manufacturing challenges and delivery system complexity among its reasons.

Why Gaps Get Missed

Design and manufacturing often get treated as two separate conversations, with manufacturing starting once design decides it’s done. The handoff looks efficient on a schedule, but by the time manufacturing gets involved, the choices that determine scale-up cost are already locked in.

Consider a custom component specified during development with a twelve-week lead time and one qualified supplier. Nothing about that choice is wrong at twenty units. At two thousand, a single quality hold at that supplier stops production, and there’s no second path to fall back on. The design team made a reasonable decision with the information in front of them, but nobody in that room owned the second-source question.

The same pattern shows up in process steps only one engineer on the design team knows how to run, and in tolerances that hold fine on a bench prototype but are expensive to hold consistently in production. None of it is obvious when the team is focused on the next development milestone. All of it becomes obvious when someone quotes the first commercial purchase order and the numbers don’t match the business plan.

This isn’t a design problem or a manufacturing problem. It’s what happens when development and manufacturing run as sequential activities instead of one commercialization process.

What Medical Device Commercialization Actually Requires

A device is commercially ready when someone other than the person who built the first one can build it the same way, at the pace and cost the business needs. Clearance answers none of that, and four areas tend to decide it.

Process documentation has to exist outside the heads of the people who built the clinical units. If it doesn’t, technology transfer becomes a rewrite instead of a handoff, and that rewrite happens under commercial schedule pressure.

The supply chain needs more than one qualified path for critical components, qualified before volume demand arrives rather than after a supplier issue forces the conversation. For a quick test, take your longest lead-time part that has one source. If that supplier called tomorrow with bad news, could you name the second source and the date it would be qualified?

The exposure is common. By PwC’s count, more than 70% of medtech memory components come from a single qualified supplier, and an end-of-life notice on one of those parts can set off a lengthy FDA requalification. The same applies to where the device gets built. If the work can’t move between sites without being rebuilt, single-region exposure is a readiness risk like any other.

The cost structure has to be modeled against real production economics. Prototype costs scaled up from a handful of lab-built units produce a number that looks fine in a deck and falls apart against production yields, scrap rates, and labor at rate. For cost, check whether the model uses yields and labor rates from an actual pilot build rather than prototype figures.

The quality system has to operate at the pace the commercial plan assumes. A QMS that handles twenty units a quarter with manual review won’t handle two thousand without redesign.

Ask Your Manufacturing Partner Whether The Design Can Scale

Those gaps are the real argument for bringing manufacturing into the room during development, not after it. Architecture, sourcing, test, and process decisions can still change at that stage, and a change then costs a design revision. After clearance, the same change can mean re-verification and possibly a new submission.

That’s a different engagement from building to a finished specification. A shop that can only build what you hand them will build it accurately, including the long-lead part, the single-sourced component, the difficult tolerance, and the process step nobody else can run. So the question to ask a manufacturing partner isn’t only “Can you build what we designed?” It’s “What can you tell us now about whether this design can actually scale?”

Related Resources

Regulatory Clearance Is Not Commercial Readiness

Learn why supply chain, process, cost, and quality gaps stall cleared devices, and why they are decided during design.

Project Estimation Pitfalls: Ten Ways Good Estimates Go Wrong

From skipping the doers to estimating toward a target budget, these ten project estimation pitfalls explain why good estimates go wrong and what to do instead.

Your device is a data business. Plan it that way from day one.

Medical device data monetization turns connected therapy data into revenue from providers, payers, and pharma, not just device sales.

Questions to Ask Before Signing a Medical Device Development Contract

Most medical device development contracts get compared on price and schedule. Here are the questions that decide what the money actually buys.